Difference between revisions of "Benralizumab (Fasenra)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
|||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
+ | ''No FDA approval for hematology/oncology conditions, at this time.'' | ||
==General information== | ==General information== | ||
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | ||
Line 5: | Line 6: | ||
*[[Hypereosinophilic syndrome (HES)]] | *[[Hypereosinophilic syndrome (HES)]] | ||
− | == | + | ==Patient Drug Information== |
− | + | *[https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/3647bed4-ce91-4fe7-9bc5-32dbee73f80a/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf Benralizumab (Fasenra) Package Insert]<ref>[https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/3647bed4-ce91-4fe7-9bc5-32dbee73f80a/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf Benralizumab (Fasenra) Package Insert]</ref> | |
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Fasenra | *'''Brand names:''' Fasenra | ||
+ | |||
+ | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 20: | Line 23: | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
+ | [[Category:Stub]] |
Latest revision as of 16:42, 27 May 2021
No FDA approval for hematology/oncology conditions, at this time.
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
Patient Drug Information
Also known as
- Brand names: Fasenra